Latest News
Del-Desiran Next Steps: Will Novartis Continue After HARBOR?
Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...
Latest News
China Out-Licensing Deals 2026: The Billion-Dollar Tracker
In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...
What EU PFAS and Microplastics Rules Mean for Cosmetics Formulators
Cosmetics regulation rarely makes it onto the radar of pharma, biotech, or medical device professionals. It probably should, at least for the next few years. The European Union is in the middle of building two overlapping restriction regimes, one for PFAS and one for...
Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision
Daiichi Sankyo and Merck have withdrawn a United States application for ifinatamab deruxtecan. The move takes a prospective small cell lung cancer treatment out of the American regulatory queue. The companies announced the withdrawal by Business Wire at 4:30pm Eastern...
Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer
The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Why Jeremy Clarkson’s Prostate Cancer Diagnosis Matters More
Last year it was Joe Biden and Barnaby Joyce who made public their diagnoses of prostate cancer. Before them, came other household names battling this condition – from Ben Stiller to Rod Stewart. This admission, on Jeremy Clarkson’s own TV show for his need of...
FDA Accelerated Approval: How the Fast-Track Pathway Works
FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....
AI Governance in Biopharma Is Failing the Translation Test
Artificial intelligence is no longer experimental in biopharma. It is operational. Across drug discovery and development, AI systems are being used to identify targets, design molecules, optimize mRNA constructs, and simulate biological interactions that were...
Beyond Animal Models: iPSC Assays Unlock the Human Brain
For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...
AI Transparency Gap in SaMD Regulation
Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment
Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...
IPA Highlights Expansion of Photodynamic Therapy in Türkiye
At the 8th Photodynamic Day of the International Photodynamic Association (IPA) held at Acıbadem University in Istanbul, speakers highlighted continued development of PDT in Türkiye and its growing clinical use internationally. Hosted by Professor Fabienne Dumoulin,...
Medicare GLP-1 Bridge: Weight-Loss Drug Coverage Begins 1st July
Starting, 1 July, millions of Medicare enrollees will gain coverage for weight-loss drugs for the first time, through a temporary pilot programme called the Medicare GLP-1 Bridge. The scheme covers Zepbound, Foundayo and Wegovy at a $50 monthly copayment and marks the...
Self-Care Isn’t Just About Feeling Good. It Helps Us Function Sustainably
Working in healthcare tends to very much not be about self-care, and yet healthcare self-care has never mattered more. It’s about caring for others, prioritising the needs of the many over yourself, and responding both physically and emotionally whilst managing an...
Weekly News Roundup | 29 June 2026
Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...
Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine
For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...
Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy
One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...
Why Jeremy Clarkson’s Prostate Cancer Diagnosis Matters More
Last year it was Joe Biden and Barnaby Joyce who made public their diagnoses of prostate cancer. Before them, came other household names battling this condition – from Ben Stiller to Rod Stewart. This admission, on Jeremy Clarkson’s own TV show for his need of...
FDA Accelerated Approval: How the Fast-Track Pathway Works
FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....
AI Governance in Biopharma Is Failing the Translation Test
Artificial intelligence is no longer experimental in biopharma. It is operational. Across drug discovery and development, AI systems are being used to identify targets, design molecules, optimize mRNA constructs, and simulate biological interactions that were...
Beyond Animal Models: iPSC Assays Unlock the Human Brain
For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...
AI Transparency Gap in SaMD Regulation
Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment
Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...
IPA Highlights Expansion of Photodynamic Therapy in Türkiye
At the 8th Photodynamic Day of the International Photodynamic Association (IPA) held at Acıbadem University in Istanbul, speakers highlighted continued development of PDT in Türkiye and its growing clinical use internationally. Hosted by Professor Fabienne Dumoulin,...
Medicare GLP-1 Bridge: Weight-Loss Drug Coverage Begins 1st July
Starting, 1 July, millions of Medicare enrollees will gain coverage for weight-loss drugs for the first time, through a temporary pilot programme called the Medicare GLP-1 Bridge. The scheme covers Zepbound, Foundayo and Wegovy at a $50 monthly copayment and marks the...
Self-Care Isn’t Just About Feeling Good. It Helps Us Function Sustainably
Working in healthcare tends to very much not be about self-care, and yet healthcare self-care has never mattered more. It’s about caring for others, prioritising the needs of the many over yourself, and responding both physically and emotionally whilst managing an...
Weekly News Roundup | 29 June 2026
Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...
Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine
For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...
Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy
One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...
Featured Articles
Further News
Merck KGaA Acquires Bio-Techne for $11.3 Billion in Life Science Tools Deal
The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...
Clinical Trials Roundup | 26 June 2026
This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...
The Role of the Microbiome in Topical Botanical Applications
The human skin is home to a complex and dynamic ecosystem of microorganisms collectively known as the skin microbiome. This microbial community - comprising bacteria, fungi, and viruses - plays a critical role in maintaining skin health, regulating immune responses,...
Beyond the Screen: Why Spinal Care Must Be Symptom-Led
In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....
New Research Reveals How Toxic Proteins Kill Brain Cells in Dementia
Findings published in Nature Communications point to a previously uncharacterised cell death mechanism that could open new therapeutic targets for slowing neurodegeneration Researchers at King's College London and the UK Dementia Research Institute have identified a...
The ‘Wild West’ of Peptide Medicine and Who’s Qualified to Prescribe
In the medical field, being “authorized” and “qualified” are two very different things. Authorized generally indicates you have the legal right to practice. Qualified means you have the expertise, experience, and skill needed to practice effectively. The distinction...
Finding AF Before It Strikes: The Case for National Screening
There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...
Creative Biolabs Discusses Antibody Library Screening Workflow
Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Why Regenerative Medicine May Reshape the Future of Spinal Fusion
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.